Healthy Returns: Trump’s FDA pick Makary may be a relief for biotech and pharma, analysts say

Trump's FDA pick, Marty Makary, appears to be quelling fears about a major disruption to biotech and pharma. Neuralink approved for new studies, company says.

View full article

...

Latest News

How President-elect Donald Trump's policies may affect investors in these 8 market sectors

2 weeks ago

UnitedHealth Group CEO addresses Brian Thompson death, says health-care system is 'flawed'

2 days ago

We want to boost our ownership of a portfolio stock that just boosted its dividend

2 days ago

We're adding to our position in a stock that just landed a big Wall Street endorsement

4 weeks ago

These innovative biotech stocks have a good chance of breaking out in 2025

2 weeks ago